The latest price target for Replimune Group (NASDAQ:REPL) was reported by BMO Capital on November 3, 2025. The analyst firm set a price target for $11.00 expecting REPL to rise to within 12 months (a ...

Multiple analysts have issued price targets for $REPL recently. We have seen 4 analysts offer price targets for $REPL in the last 6 months, with a median target of ...

Short interest in Replimune Group Inc (NASDAQ:REPL) decreased during the last reporting period, falling from 15.27M to 14.76M. This put 35.19% of the company's publicly available shares short. Based ...

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic ...

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...